Clinical trial
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and…
NCT00167999 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00167999 |
|---|---|
| Title | Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units |
| Official title | Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections |
| Intervention type | Drug |
| Interventions | piperacillin-tazobactam |
| Enrollment | 200 |
| Start date | Feb 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Mar 15, 2007 |
| Countries | South Korea |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: